GLP-1 prices in 2026: the self-pay programs, the new pills, and the Medicare bridge
The cost of Wegovy, Zepbound and the newer GLP-1 pills has changed more in 2026 than in any year since they launched: two oral options, manufacturer self-pay programs priced by dose, a Medicare bridge program and an announced list-price cut. Here is what changed and what it means if you pay yourself.
Updated October 3, 2026
What happened
- December 2025The FDA approved an oral form of Wegovy (semaglutide tablets) for weight management.
- February 2026Novo Nordisk announced a list-price cut for Wegovy, Ozempic and Rybelsus taking effect in January 2027, saying its self-pay prices were unaffected.
- April 2026The FDA approved orforglipron, sold as Foundayo, Eli Lilly’s daily GLP-1 pill for weight management.
- July 2026A Medicare GLP-1 bridge program began, letting eligible Part D enrollees get some obesity GLP-1s for a flat monthly copay through the end of 2027.
Three ways to pay, and which applies to you
If your commercial insurance covers a GLP-1, the copay with the manufacturer’s savings card is almost always the least you will pay. If you are on Medicare Part D and eligible for the bridge program, its flat copay applies to the listed drugs. If you have no coverage for weight management, which is common, the manufacturers’ self-pay programs, NovoCare for Wegovy and LillyDirect for Zepbound and Foundayo, sell at prices set by dose, well below list, either shipped directly or through partner pharmacies. TrumpRx links to the same programs.
Where a local pharmacy fits
A local pharmacy filling a brand GLP-1 for cash buys it at wholesale, close to list price, so its cash quote is usually far above the self-pay programs unless it is a partner pharmacy for one of them. Where pharmacies do compete is on the drugs that are generic: liraglutide, the older daily GLP-1, now has generic versions, and generic diabetes medicines such as metformin, glipizide and pioglitazone remain inexpensive options for blood sugar.
Compounded semaglutide and tirzepatide were widely sold during the shortages. With the shortages over, the FDA has tightened its position on copies of approved drugs, and quality between compounders varies; our semaglutide guide sets out the position.
What to watch next
The announced list-price cut in January 2027 mainly affects insured patients whose coinsurance is based on list price. Semaglutide is also among the drugs with Medicare-negotiated prices taking effect in 2027. Further oral GLP-1s are in development, and new entrants have so far been accompanied by lower self-pay prices.
What to do
- Check whether your plan covers the drug for your diagnosis and, if so, use the manufacturer savings card.
- If you are on Medicare, ask whether you qualify for the GLP-1 bridge program.
- Without coverage, compare the manufacturer self-pay price for your dose with any pharmacy quote.
- Ask your prescriber whether generic liraglutide or a generic diabetes medicine would suit you.
Upload it and licensed pharmacies reply with their own cash price. You pay the pharmacy, not us.
Related
Sources
- The Rx Index, GLP-1 price and access tracker
- HealthCount, what GLP-1 medications cost in the US in 2026
- FDA, information on GLP-1 drugs and compounding
- Centers for Medicare & Medicaid Services
Written by the Script Unlock editorial team from the reporting and official sources above, as of October 3, 2026. Policies and prices in this area change often; check the linked sources for the latest.
Script Unlock is a marketplace that lets licensed pharmacies quote a cash price on your prescription. It does not prescribe, dispense or sell medication, does not process patient payments, and does not give medical advice. Always follow the instructions of your prescriber and pharmacist and read the medication guide supplied with your medicine.